AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11149033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine + Mannitol (0.25 g/kg every 12 hours for 2 postoperative days)
Number of subjects: 40
Study 11149033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine + Furosemide (1 mg/kg every 12 hours for 2 postoperative days)
Number of subjects: 40
Study 11149033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 9489083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat core (CC) 10 mg o.d.
Number of subjects: 0
Study 9489083 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg o.d.
Number of subjects: 0
Study 9489083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat core (CC)
Number of subjects: 0
Study 9489083 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 7691765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate in non-thrombolytic group
Number of subjects: 109
Study 7691765 — intervention group
Group type: COMPARATOR
Intervention: Ongoing fibrinolytic therapy
Number of subjects: 109
Study 2864032 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based approach
Number of subjects: 36
Study 2864032 — intervention group
Group type: COMPARATOR
Intervention: Patient-oriented approach
Number of subjects: 36
Study 31424431 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based education (video and 3D animations)
Number of subjects: 0
Study 31424431 — intervention group
Group type: COMPARATOR
Intervention: Nurse counseling (standard of care)
Number of subjects: 0
Study 31424431 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based education
Number of subjects: 0
Study 29486348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning Relationships with Music (intervention)
Number of subjects: 26
Study 29486348 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 26
Study 27807527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise group (SEG, n=34)
Number of subjects: 57
Study 27807527 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy group (PTG, n=23)
Number of subjects: 57
Study 24508042 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine administered according to a 2-dose vaccination schedule (0, 12 months in study A and 0, 6 months in study B)
Number of subjects: 281
Study 24508042 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models for longitudinal data
Number of subjects: 281
Study 22528571 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn CEGA
Number of subjects: 174
Study 22528571 — intervention group
Group type: COMPARATOR
Intervention: Stapled side-to-side CEGA
Number of subjects: 174
Study 20583919 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical approach (TG)
Number of subjects: 30
Study 20583919 — intervention group
Group type: COMPARATOR
Intervention: Conventional macrosurgical technique (CG)
Number of subjects: 30
Study 20583919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study 17908322 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Emergency Nurses (SEN)
Number of subjects: 0
Study 17908322 — intervention group
Group type: COMPARATOR
Intervention: House Officers (HOs)
Number of subjects: 0
Study 16061589 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 898
Study 16061589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898
Study 16061589 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional analgesia with morphine
Number of subjects: 898
Study 12370838 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS monotherapy (20 mg/d)
Number of subjects: 20
Study 12370838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (2.5 g/d)
Number of subjects: 20
Study 12370838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (glipizide GITS + metformin)
Number of subjects: 20
Study 12370838 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (either glipizide GITS or metformin)
Number of subjects: 20
Study 10077140 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 0
Study 10077140 — intervention group
Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 0
Study 7672959 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback training (n = 8)
Number of subjects: 26
Study 7672959 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius EMG biofeedback training (n = 10)
Number of subjects: 26
Study 7672959 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation therapy (n = 8)
Number of subjects: 26
Study 2149882 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (high doses: 300-600 mg daily)
Number of subjects: 0
Study 2149882 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 7023649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly methotrexate
Number of subjects: 259
Study 7023649 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly methotrexate with leucovorin rescue (ML)
Number of subjects: 259
Study 7023649 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly ML combined with cyclophosphamide and cytosine arabinoside (MLCC)
Number of subjects: 259
Study 7023649 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 259
Study 7023649 — intervention group
Group type: COMPARATOR
Intervention: MLCC
Number of subjects: 259
Study 31578895 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based salivary cortisol collection protocol
Number of subjects: 188
Study 31067067 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Superior Alveolar (MSA) technique
Number of subjects: 30
Study 31067067 — intervention group
Group type: COMPARATOR
Intervention: Infraorbital technique
Number of subjects: 30
Study 28751519 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus CT characteristics (location, distance from ICA terminus to thrombus, length, volume, absolute and relative density on NCCT, and perviousness)
Number of subjects: 199
Study 28751519 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial treatment
Number of subjects: 199
Study 26540210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined home health education (HHE) plus trained general practitioner (GP) intervention
Number of subjects: 1341
Study 26540210 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1341
Study 23484176 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide bleaching gel
Number of subjects: 22
Study 23484176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20955400 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine withdrawal
Number of subjects: 124
Study 20955400 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate withdrawal
Number of subjects: 124
Study 19150180 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized laboratory speech stressor
Number of subjects: 28
Study 19150180 — intervention group
Group type: COMPARATOR
Intervention: Control task (no stressor)
Number of subjects: 28
Study 19150180 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests performed the day after the stressor
Number of subjects: 28
Study 19150180 — intervention group
Group type: EXPERIMENTAL
Intervention: Con A-stimulated leukocytes post-stressor
Number of subjects: 28
Study 18321465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + PDT
Number of subjects: 162
Study 18321465 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study 16033337 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice (glucose 28 g in 250 ml) administered at 06:00‐06:30 am
Number of subjects: 100
Study 16033337 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 100
Study 12109009 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class Web survey
Number of subjects: 0
Study 12109009 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class paper-and-pencil survey
Number of subjects: 0
Study 12109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home Web survey
Number of subjects: 0
Study 12109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home paper-and-pencil survey
Number of subjects: 0
Study 11692351 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional video glasses
Number of subjects: 24
Study 11692351 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional video glasses
Number of subjects: 24
Study 11692351 — intervention group
Group type: COMPARATOR
Intervention: No video glasses (control)
Number of subjects: 24
Study 7498222 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC
Number of subjects: 15
Study 7498222 — intervention group
Group type: COMPARATOR
Intervention: 131I‐OIH
Number of subjects: 15
Study 2100642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pliva 60 diltiazem preparation
Number of subjects: 9
Study 2100642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pliva 90 diltiazem preparation
Number of subjects: 9
Study 2100642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldizem 90 diltiazem preparation
Number of subjects: 9
Study 6800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Y vaccine
Number of subjects: 10
Study 6800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W135 vaccine
Number of subjects: 10
Study 6800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Y-W135 combined vaccine
Number of subjects: 10
Study 6800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent vaccine (50 micrograms)
Number of subjects: 10
Study 6800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalent vaccine (100 micrograms)
Number of subjects: 10
Study 31740114 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 104
Study 31740114 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II or HeartWare Ventricular Assist Device (Control)
Number of subjects: 104
Study 30157894 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIS treatment (pre‐post‐follow‐up)
Number of subjects: 56
Study 30157894 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC, pre‐post)
Number of subjects: 56
Study 27161339 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO (Experienced Carer Helping Others) intervention
Number of subjects: 149
Study 27161339 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 149
Study 27161339 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO intervention
Number of subjects: 149
Study 27161339 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO and TAU
Number of subjects: 149
Study 25490732 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief parent-adolescent sexual risk communication intervention
Number of subjects: 2564
Study 22205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 35 mg/m(2) in < 65 years group
Number of subjects: 93
Study 22205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 20 mg/m(2) in ≥ 65 years group
Number of subjects: 93
Study 22205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Bortezomib, Gemcitabine, Liposomal Doxorubicin)
Number of subjects: 93
Study 20631326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc administration (10 mg/d for children 2-11 months and 20 mg/d for children ≥ 12 months) for 14 days
Number of subjects: 2599
Study 20631326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2599
Study 20631326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc administration
Number of subjects: 2599
Study 18551467 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Number of subjects: 0
Study 18551467 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Number of subjects: 0
Study 18551467 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (0.3 g extract/250 ml) with 5 mg folic acid
Number of subjects: 0
Study 18551467 — intervention group
Group type: COMPARATOR
Intervention: Water (reference drink) with 0.4 mg and 5 mg folic acid
Number of subjects: 0
Study 17002050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy regimen '2b' (isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolone (ofloxacin, ciprofloxacin, levofloxacin), and canamycin (amikacin))
Number of subjects: 75
Study 17002050 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen '2a' (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin)
Number of subjects: 75
Study 17002050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy regimen '2b'
Number of subjects: 75
Study 17002050 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen '2a'
Number of subjects: 75
Study 17002050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in patients with MBT resistant to isoniazid
Number of subjects: 75
Study 17002050 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen '2a' in patients with MBT resistant to isoniazid
Number of subjects: 75
Study 17002050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in patients with MBT resistant to rifampicin
Number of subjects: 75
Study 17002050 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen '2a' in patients with MBT resistant to rifampicin
Number of subjects: 75
Study 17002050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in multidrug resistance
Number of subjects: 75
Study 17002050 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen '2a' in multidrug resistance
Number of subjects: 75
Study 12925338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular exercises (13 patients)
Number of subjects: 21
Study 12925338 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercises (8 patients)
Number of subjects: 21
Study 10375149 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer Assessment of Behavioral Health Services instrument
Number of subjects: 160
Study 8931918 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic children
Number of subjects: 57
Study 8931918 — intervention group
Group type: COMPARATOR
Intervention: ADHD children
Number of subjects: 57
Study 8931918 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 57
Study 1706562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 4 mg + Cimetidine 400 mg i.v. 15 min before implantation
Number of subjects: 40
Study 1706562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 40
Study 1706562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement implantation
Number of subjects: 40
Study 6765509 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of triamcinolonehexacetonide (TH)
Number of subjects: 42
Study 6765509 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of the combination betamethasone acetate and betamethasone disodiumphosphate (BM)
Number of subjects: 42
Study 31647382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) response
Number of subjects: 0
Study 31647382 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 28685396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCl immediate release (IR) 75 mg
Number of subjects: 0
Study 28685396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCl sustained release (SR) 100/150 mg
Number of subjects: 0
Study 28685396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCl extended release (ER) 150/300 mg
Number of subjects: 0
Study 25554008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-standardized compression (10 kPa)
Number of subjects: 433
Study 25554008 — intervention group
Group type: COMPARATOR
Intervention: Force-standardized compression (14 daN)
Number of subjects: 433
Study 24238630 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based treatment program
Number of subjects: 0
Study 24238630 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 21336185 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 28
Study 21336185 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 28
Study 20144171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg)
Number of subjects: 480
Study 20144171 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (50 microg)
Number of subjects: 480
Study 17885577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (open-label and double-blind)
Number of subjects: 54
Study 17885577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 54
Study 15502058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 54
Study 15502058 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil
Number of subjects: 54
Study 15502058 — intervention group
Group type: COMPARATOR
Intervention: Propofol/sufentanil
Number of subjects: 54
Study 11181092 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 11181092 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9786345 — intervention group
Group type: EXPERIMENTAL
Intervention: Early morning blood collection
Number of subjects: 657
Study 7874154 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP‐E (0.2 g.kg‐1.day‐1)
Number of subjects: 12
Study 3282867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained action tiaprofenic acid 600 mg once daily
Number of subjects: 98
Study 3282867 — intervention group
Group type: COMPARATOR
Intervention: Sustained release indomethacin 75 mg once daily
Number of subjects: 98
Study 31811952 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (2-3 sessions combined with daily exercise)
Number of subjects: 50
Study 31811952 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber supplementation (3.5 g plantago ovata per day)
Number of subjects: 50
Study 31654837 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 0
Study 31654837 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 28336105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low polyamine diet (group 1)
Number of subjects: 0
Study 28336105 — intervention group
Group type: COMPARATOR
Intervention: Partial polyamine diet (group 2)
Number of subjects: 0
Study 25351805 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nuts
Number of subjects: 17
Study 25351805 — intervention group
Group type: COMPARATOR
Intervention: Macronutrient-matched control snack
Number of subjects: 17
Study 23477538 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (n = 3148)
Number of subjects: 5347
Study 23477538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2199)
Number of subjects: 5347
Study 21720264 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 855
Study 21720264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 855
Study 19794985 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-extract isoflavones
Number of subjects: 53
Study 19794985 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 53
Study 19794985 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein low-excretors
Number of subjects: 53
Study 16333546 — intervention group
Group type: COMPARATOR
Intervention: Raw CO2 (group 1)
Number of subjects: 44
Study 16333546 — intervention group
Group type: COMPARATOR
Intervention: Heated CO2 (group 2)
Number of subjects: 44
Study 16333546 — intervention group
Group type: COMPARATOR
Intervention: Humidified CO2 (group 3)
Number of subjects: 44
Study 16333546 — intervention group
Group type: COMPARATOR
Intervention: Heated and humidified CO2 (group 4)
Number of subjects: 44
Study 15339440 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-application of manipulation
Number of subjects: 242
Study 15339440 — intervention group
Group type: EXPERIMENTAL
Intervention: Union-application of manipulation
Number of subjects: 242
Study 11168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap oscillometric device
Number of subjects: 79
Study 11168303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmomanometer
Number of subjects: 79
Study 11168303 — intervention group
Group type: COMPARATOR
Intervention: Both methods (Dinamap and sphygmomanometer)
Number of subjects: 79
Study 9579209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of meglumine antimoniate (MA; 15 mg Sb/kg.day) on 6 days/week for 12 injections.
Number of subjects: 80
Study 9579209 — intervention group
Group type: COMPARATOR
Intervention: Intralesional administration of meglumine antimoniate (MA; 0.2‐0.8 ml/lesion) every other day for 30 days.
Number of subjects: 80
Study 8200946 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human CNP‐22 (5 pmol/kg.min)
Number of subjects: 9
Study 8200946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8200946 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP during coinfusion of angiotensin‐II
Number of subjects: 9
Study 3300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.0075 mg/kg/day)
Number of subjects: 30
Study 3300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.015 mg/kg/day)
Number of subjects: 30
Study 3300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (twice a day)
Number of subjects: 30
Study 3300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (in patients receiving neuroleptic agents)
Number of subjects: 30
Study 3300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (low dose vs high dose)
Number of subjects: 30